.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 4,220,660

« Back to Dashboard

Claims for Patent: 4,220,660

Title: Process for the treatment of humans suffering from undesired urotoxic side effects caused by cytostatically active alkylating agents
Abstract:The invention is related to a process for the treatment of humans suffering from undesired urotoxic side effects caused by cytostatically active alkylating agents administered to them against malign tumors, comprising administering a pharmacologically acceptable salt of a mercapto alkane sulfonic acid having the general formula to the human treated with the cytostatically active alkylating agent, in an amount ranging from 20% of the weight of the alkylating agent to the highest tolerated dosage of the salt of the mercapto alkane sulfonic acid, simultaneously or separately in combination with the alkylating agent.
Inventor(s): Brock; Norbert (Bielefeld, DE)
Assignee: Asta-werke Aktiengesellschaft, Chemische Farik (Bielefeld, DE)
Application Number:05/967,000
Patent Claims: 1. Process for the treatment of humans suffering from the undesired urotoxic side effects caused by cytostatically active alkylating agents selected from the group consisting of cyclophosphamide, trofosfamide, ifosfamide, and sufosfamide in the kidneys, urinary tracts and urinary bladder comprising administering a pharmacologically acceptable salt of a mercapto alkane sulfonic acid having the general formula

wherein alk is a member selected from the group consisting of the straight and branched alkylene groups having from 2 to 6 carbon atoms, to the human treated with the alkylating agent in an amount ranging from 20% to about 100% of the weight of the dose of the alkylating agent of the salt of the mercapto alkane sulfonic acid.

2. Process as claimed in claim 1 wherein the salt of the mercapto alkane sulfonic acid is administered to the patient within the period ranging from about 30 minutes before the administration of the cytostatically active alkylating agent up to about 30 minutes after its administration.

3. Process as claimed in claim 1 wherein at least 25% of the total dose of the salt of the mercapto alkane sulfonic acid is administered in a period ranging from about 30 minutes before the administration of the cytostatically active alkylating agent until about 30 minutes after its administration while the remainder of the total dose is administered to the human in a single or in several separate partial doses within a period of up to 12 hours after the administration of the cytostatically active alkylating agent.

4. Process as claimed in claim 1 wherein the salt of the mercapto alkane sulfonic acid is administered to the human in an amount ranging from 30 to 100% of the weight of the dose of the cytostatically active alkylating agent.

5. Process as claimed in claim 1 wherein alk is the 1,2-ethylene group.

6. Process as claimed in claim 1 wherein the pharmacologically acceptable salt of the mercapto alkane sulfonic acid is an alkali metal salt.

7. Process as claimed in claim 6 wherein the pharmacologically acceptable salt is the sodium salt.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc